NCH Rooney Heart Institute announces they are Among First in the Nation

NCH Rooney Heart Institute Among First in Nation to Offer FDA Approved Medtronic Mosaic™ Neo Mitral Valve

The NCH Rooney Heart Institute is among the first in the United States to offer the newly FDA-approved Medtronic Mosaic™ Neo surgical mitral valve, marking a significant advancement in the treatment of patients requiring mitral valve replacement.

The innovative bioprosthetic valve, recently approved by the U.S. Food and Drug Administration (FDA), expands surgical options for patients with mitral valve disease, offering enhanced durability and improved performance.

The Medtronic Mosaic Neo Mitral Valve is designed to provide a durable, tissue-based replacement option for patients requiring mitral valve intervention, particularly those who may not be candidates for long-term anticoagulation therapy. Built on a legacy platform with enhanced design features, the valve aims to optimize hemodynamic performance while supporting ease of implantation for cardiac surgeons. Its development reflects continued advancements in structural heart technology focused on improving patient outcomes, reducing complications, and expanding treatment options for individuals with complex valvular disease.

The first procedures at NCH were performed by leading cardiothoracic surgeons Joseph Lamelas, MD, and Tommy Caranasos, MD, underscoring the Institute’s continued commitment to bringing advanced cardiac care to Southwest Florida.

Dr Joseph Lamelas MD

“This new valve technology represents an important step forward in how we treat complex mitral valve disease,” said Joseph Lamelas, MD, Director, Minimally Invasive Heart Surgery Program at NCH Rooney Heart Institute. “Being among the first to offer Mosaic Neo allows us to provide our patients with the latest surgical innovations while maintaining the highest standards of safety and outcomes.”

“Our goal is always to match the right therapy to the right patient,” said Tommy Caranasos, MD, (Featured Photo) Vice president, NCH Rooney Heart Institute and the James and Jaimie Yeh Endowed Chair. “The availability of Mosaic Neo enhances our ability to tailor surgical solutions and improve long-term quality of life for those we serve.”

The milestone reflects the NCH Rooney Heart Institute’s ongoing investment in cutting-edge cardiovascular therapies, clinical expertise, and patient-centered care. As one of the region’s leading heart programs, the Institute continues to expand access to advanced procedures typically available only at major academic medical centers.

About NCH
Naples Comprehensive Health (NCH) is an advanced community healthcare system serving Southwest Florida with premier routine, critical, and specialty care. A locally governed nonprofit, NCH has been recognized among America’s Top 50 hospitals which puts it in the top 1% in the nation for clinical excellence. It was also named a Top 50 Cardiovascular Hospital by Modern Healthcare. The system includes NCH Baker Hospital and NCH North Hospital, with more than 700 beds and more than 750 physicians, along with medical facilities in dozens of locations throughout Southwest Florida. NCH is the region’s only Joint Commission-accredited Comprehensive Stroke Center, and its cardiac care program ranks among the top three in the state. NCH collaborates with the Hospital for Special Surgery for orthopedics, Nicklaus Children’s Hospital for pediatrics, and ProScan Imaging for radiology services, ensuring top-tier medical care is available locally. With the largest provider network, urgent and immediate care centers, diagnostic facilities, and two hospitals, NCH continues to advance the quality of care close to home. For more information, visit nchmd.org.